Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502169 | 1.00 | MAPT (0.59) | MAPTLMNATP53ADORA3ADORA2A | |
| SCHEMBL29414385 | 0.85 | LMNA (0.56) | MAPTLMNAADORA3ADORA2AADORA2B | |
| SCHEMBL1519715 | 0.85 | LMNA (0.56) | MAPTLMNAADORA3ADORA2AADORA2B | |
| SCHEMBL7968233 | 0.82 | GRIA1 (0.56) | MAPTLMNATP53METAP2AURKA | |
| SCHEMBL30581043 | 0.80 | ADORA3 (0.61) | MAPTLMNAADORA3ADORA2AADORA2B | |
| SCHEMBL3376884 | 0.80 | ADORA3 (0.61) | MAPTLMNAADORA3ADORA2AADORA2B | |
| SCHEMBL3263393 | 0.79 | DAO (0.66) | MAPTLMNATP53ADORA3ADORA2A | |
| SCHEMBL29714929 | 0.79 | PARG (0.49) | MAPTLMNATP53ADORA3ADORA2A | |
| SCHEMBL22745861 | 0.79 | PARG (0.49) | MAPTLMNATP53ADORA3ADORA2A | |
| SCHEMBL25318060 | 0.78 | LMNA (0.56) | MAPTLMNATP53ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003517459-A | — | — | 2003-05-27 | — | — | JP | claimed |
| EP-1173423-A1 | BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | claimed |
| WO-2000066564-A1 | BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250320206-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-8987249-B2 | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| WO-2014140075-A1 | SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275025-A1 | SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-2603079-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Merck Sharp & Dohme Corp. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012172043-A1 | PURINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS FOR PREVENTION OR TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRE BIODIM (FR) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | MAPT 2453/4885LMNA 1708/4885TP53 3791/4885 |
| US-20140275025-A1 | SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSB, CTSG | MAPT 4733/4885LMNA 735/4885TP53 2589/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | MAPT 1734/4885LMNA 1466/4885TP53 1338/4885 |
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | MAPT 1017/4885LMNA 2978/4885TP53 10/4885 |
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | MAPT 3915/4885LMNA 3597/4885TP53 4806/4885 |
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | MAPT 4092/4885LMNA 4532/4885TP53 130/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | MAPT 1371/4885LMNA 1086/4885TP53 7/4885 |
| US-20250320206-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | MAPT 1017/4885LMNA 2978/4885TP53 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.